KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
about
KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
KRAS-mutation status dependent ...... ell cancer preclinical models.
@en
KRAS-mutation status dependent ...... ell cancer preclinical models.
@nl
type
label
KRAS-mutation status dependent ...... ell cancer preclinical models.
@en
KRAS-mutation status dependent ...... ell cancer preclinical models.
@nl
prefLabel
KRAS-mutation status dependent ...... ell cancer preclinical models.
@en
KRAS-mutation status dependent ...... ell cancer preclinical models.
@nl
P2093
P2860
P356
P1433
P1476
KRAS-mutation status dependent ...... ell cancer preclinical models.
@en
P2093
Dávid Molnár
István Kenessey
Judit Dobos
József Tímár
József Tóvári
Krisztina Kói
Orsolya Horváth
Vera Izsák
P2860
P304
79503-79514
P356
10.18632/ONCOTARGET.12806
P407
P577
2016-10-21T00:00:00Z